Maximizing benefit of drug-eluting stent by direct coronary stenting because of further reduction of inflammatory response

Chinese Medical Journal

Volumn 122, Issue 6, 2009, Pages 732-735

  Li, Jian Jun ^a   Gao, Run Lin ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Direct stenting; Drug eluting stent; Inflammation; Restenosis

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; PACLITAXEL; RAPAMYCIN; TUMOR NECROSIS FACTOR ALPHA; ZOTAROLIMUS;

ANTIINFLAMMATORY ACTIVITY; ARTERY INTIMA PROLIFERATION; ARTICLE; BARE METAL STENT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG ELUTING STENT; ENDOTHELIAL DYSFUNCTION; HUMAN; IN-STENT RESTENOSIS; INFLAMMATION; PATIENT SAFETY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PROTEIN EXPRESSION; THERAPY EFFECT; TREATMENT OUTCOME; IMMUNOLOGY; INSTRUMENTATION; METHODOLOGY; RESTENOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY RESTENOSIS; DRUG-ELUTING STENTS;

EID: 67649784577     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2009.06.026     Document Type: Article

References (28)

1. Li JJ. Inflammatory response, drug-eluting stent, and restenosis. Chin Med J 2008; 121: 566-572.
2. Li JJ, Xu B, Yang YJ, Chen JL, Qiao SB, Ma WH, et al. Is there delayed restensosis in patients with coronary artery disease treated with sirolimus-eluting stent? Coron Artery Dis 2007; 18: 293-298.
3. Moses JW, Weisz G, Mishkel G, Caputo R, O'Shaughnessey C, Wong SC, et al. The SIRIUS-DIRECT trial: a multi-center study of direct stenting using the sirolimus-eluting stent in patients with de novo native coronary artery lesions. Catherter Cardiovasc Interv 2007; 70: 505-512.
4. Bass TA. Direct stenting in the DES era: can we do better? Catherter Cardiovasc Interv 2007; 70: 513-514.
5. Ijsselmuiden AJ, Serruys PW, Scholte A, Kiemeneij F, Slagboom T, vd Wieken LR, et al. Direct coronary stent implantation does not reduce the incidence of in-stent restenosis or major adverse cardiac events. Eur Heart J 2003; 24: 421-429.
6. Lowe HC, Oesterle SN, Khachigian LM. Coronary in-stent restenosis: current status and future strategies. J Am Coll Cardiol 2002; 39: 183-193.
7. Bennett MR. In-stent restenosis: pathology and implications for the development of drug eluting stent. Heart 2003; 89: 218-214.
8. Li JJ, Xu B, Yang YJ, Chen JL, Qiao SB, Ma WH, et al. A comparison of angiographic and clinical outcome after sirolimus-eluting versus paclitaxel-eluting stents for the treatment of in-stent restenosis. Chin Med J 2006; 119: 1059-1064.
9. Li JJ, Xu B, Yang YJ, Chen JL, Qiao SB, Ma WH, et al. Drug-eluting stent for the treatment of small coronary lesions: comparison between sirolimus- and paclitaxel-eluting stent. Chin Med J 2007; 120: 569-573.
10. Chen J, Li JJ, Chen JL, Xu B, Yang YJ, Qiao SB, et al. Drug-eluting stents for the treatment of ostial coronary lesions: comparison sirolimus-eluting stent with paclitaxel-eluting stent. Coron Artery Dis 2008; 19: 507-511.
11. Li JJ, Xu B, Yang YJ, Chen JL, Qiao SB, Ma WH, et al. Effects of sirolimus-eluting stent on calcified coronary lesions. Chin Med J 2008; 121: 6-11.
12. Rodriguez-Granillo GA, Valgimigli M, Garcia-Garcia HM, Mng AT, Aoki J, van Mieghem CA, et al. One-year clinical outcome after coronary stenting of very small vessels using 2.25 mm sirolimus- and paclitaxel-eluting stents: a comparison between the RESEARCH and T-SEARCH registries. J Invasive Cardiol 2005; 17: 413-414.
13. Li JJ, Li J, Nan JL, Li Z, Zhen X, Mu CW, et al. Coronary restenotic reduction of drug-eluting stenting may be due to its anti-inflammatory effect. Med Hypotheses 2007; 69: 1004-1009.
14. Li JJ, Qin XW, Yang XC, Li ZC, Zeng HS, Xu B, et al. Randomized comparison of early inflammatory response after sirolimus-eluting stent versus bare metal stent implantation in native coronary lesions. Clin Chim Acta 2008; 396: 38-42.
15. Nuhrenberg TG, Voisard R, Fahlisch F, Rudelius M, Braun J, Gschwend J, et al. Rapamycin attenuates vascular wall inflammation and progenitor cell promoters after angioplasty. FASEB J 2005; 19: 246-248.
16. Adkins JR, Castresana MR, Wang Z, Newman WH. Rapamycin inhibits release of tumor necrosis factor-alpha from human vascular smooth muscle cells. Am Surg 2004; 70: 384-387.
17. Li JJ, Nie SP, Zhang CY, Gao Z, Zheng X, Guo YL. Is inflammation a contributor for in-stent restenosis? Med Hypotheses 2007; 68: 945-951.
18. Barbato E, Marco J, Wijns W. Direct stenting. Eur Heart J 2003; 24: 394-403.
19. Larrazet F, Philippe E, Caussin C, Lancelin B, Aptecar E, Pernes JM, et al. Feasibility, safety, cost-effectiveness and 1 year follow-up of coronary stenting without predilatation: a matched comparison with the standard approach. Int J Cardiol 2001; 80: 187-192.
20. Burzotta F, Trani C, Prati F, Hamon M, Mazzari MA, Monqiardo R, et al. Comparison of outcomes (early and six-month) of direct stenting with conventional stenting (a meta-analysis of ten randomized trials). Am J Cardiol 2003; 91: 790-796.
21. Ortolani P, Ardissino D, Cavallini C, Bramucci E, Indolfi C, Aquilina M, et al. Effect of sirolimus-eluting stent in diabetic patients with small coronary arteries (a SES-SMART substudy). Am J Cardiol 2005; 96: 1393-1398.
22. Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries; double-blind, randomized controlled trial (E-SIRIUS). Lancet 2003; 362: 1093-1099.
23. Inoue T, Kato T, Uchida T, Sakuma M, Nakajina A, Shibazaki M, et al. Local release of C-reactive protein from vulnerable plaque or coronary arterial wall injured by stenting. J Am Coll Cardiol 2005; 46: 239-245.
24. Li JJ, Fang CH, Jiang H, Huang CX, Hui RT, Chen MZ. Time course of inflammatory response after renal artery stenting in patients with atherosclerotic renal artery stenosis. Clin Chim Acta 2004; 350: 115-121.
25. Gibson CM, Karmpaliotis D, Kosmidou I, Murphy SA, Kirtane AJ, Budiu D, et al. Comparison of effects of bare metal versus drug-eluting stent implantation on biomarker levels following percutaenous coronary intervention for non-ST-elevation acute coronary syndrome. Am J Cardiol 2006; 97: 1473-1477.
26. Kim JY, Ko YG, Shim CY, Park S, Hwang KC, Choi D, et al. Comparison of effects of drug-eluting stents versus bare metal stents on plasma C-reactive protein levels. Am J Cardiol 2005; 96: 1384-1388.
27. Brasselet C, Garnotel R, Perotin S, Vitry F, Elaerts J, Lafont A, et al. Percutaneous coronary intervention-induced variations in systemic parameters of inflammation: relationship with the model of stenting. Clin Chem Lab Med 2007; 45: 526-530.
28. Li JJ, Zhang YP, Wan C, Gao LJ, Qin XW, Xu B, et al. Impact of direct sirolimus-eluting stent implantation on early inflammatory response compared with complementary stenting. Coron Artery Dis 2009; 20: 65-70.